Gushengtang steps up TCM buying spree, doubling down in Beijing
The healthcare company has announced five acquisitions in the past two weeks to shore up growth and fend off competition in the traditional Chinese medicine market Key Takeaways: Gushengtang is…
Drug setback leaves Ascletis with an all-in bet on weight loss
The company’s two core hepatitis drugs were dropped from China’s state insurance scheme on July 1, effectively wiping out the remains of its legacy drug sales Key Takeaways: The company…
Tong Ren Tang Healthcare makes trading debut, backed by 39% annual patient growth
The company will use a majority of the $68 million it raised from its Hong Kong listing to expand its network of traditional Chinese medicine hospitals and clinics Key Takeaways:…
Alebund soars in Hong Kong debut on kidney treatment hopes
The drug developer stood out from the IPO crowd of unprofitable biotechs due to its existing revenue stream and a focus on novel remedies for renal disease Key Takeaways: Alebund…
JBM Healthcare gets bitter pill from investors on anemic performance
Shares of the over-the-counter traditional Chinese medicine company tumbled after it reported sequential revenue and profit declines in the second half of its fiscal year Key Takeaways: JBM Healthcare’s profit…
CSPC Innovation pursues Hong Kong IPO as parent profits shrink
The producer of food additives and pharmaceutical ingredients is aiming to raise fresh capital to support its drive to become a developer of innovative drugs Key takeaways: R&D costs have…
Chinese ‘Easter Eggs’ fall back to earth after wild year on Wall Street
Shares of Here Group, Zepp Health, Burning Rock Biotech and So-Young International all posted meteoric gains last year, but have given most of that back in 2026 Key Takeaways: A…
